Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 3.00
High: 0.00
Low: 0.00
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Jun 2017 12:55

RNS Number : 0263H
Allergy Therapeutics PLC
02 June 2017
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Allergy Therapeutics PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

S

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

¨

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

¨

An event changing the breakdown of voting rights

¨

Other (please specify):

¨

3. Full name of person(s) subject to thenotification obligation: iii

BlackRock, Inc.

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

1 June, 2017

6. Date on which issuer notified:

2 June, 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

Voting rights attached to shares holding for BlackRock Investment Management (UK) Limited has gone above 5%

 

Total holding for BlackRock Investment Management (UK) Limited has gone above 5%

 

Voting rights attached to shares holding for BlackRock, Inc. has gone above 5%

 

Total holding for BlackRock, Inc. has gone above 5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

GB00B02LCQ05

Below 5%

Below 5%

N/A

N/A

30,368,413

N/A

5.11%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

30,368,413

5.11%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

See Annex 1

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

BlackRock Regulatory Threshold Reporting Team

14. Contact name:

Marc-Oliver Lesch

15. Contact telephone number:

020 7743 3650

Annex 1

 

Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

BlackRock, Inc.

BlackRock Holdco 2, Inc.

BlackRock Financial Management, Inc.

BlackRock International Holdings, Inc.

BR Jersey International Holdings L.P.

BlackRock Group Limited

BlackRock Investment Management (UK) Limited

5.11%

5.11%

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUVARBSANRAR
Date   Source Headline
20th Jun 202312:49 pmRNSForm 8.5 - Allergy Therapeutics plc
20th Jun 20239:57 amBUSForm 8.3 - The Allergy Therapeutics Plc
20th Jun 20239:05 amRNSForm 8.5 (EPT/RI)
19th Jun 20237:30 amRNSRestoration - Allergy Therapeutics PLC
19th Jun 20237:01 amRNSInterim Results and Lifting Suspension in Trading
19th Jun 20237:00 amRNSPublication of Annual Report and Accounts 2022
9th Jun 20237:00 amRNSAllergy Therapeutics shares key findings at EAACI
3rd May 20239:09 amRNSForm 8.3 - Allergy Therapeutics plc
27th Apr 20232:15 pmRNSResult of General Meeting
24th Apr 20237:00 amRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc
21st Apr 20237:00 amRNSFORM 8 (OPD) – Allergy Therapeutics plc
20th Apr 20235:29 pmRNSProject Zebra Rule 2.9 Announcement
19th Apr 20237:00 amRNSSkin-prick testing completes in PROTECT Trial
17th Apr 20232:30 pmRNSForm 8 OPD SkyGem Acquisition Limited Replacement
17th Apr 202310:30 amRNSForm 8 (OPD) SkyGem Acquisition Limited
11th Apr 202310:10 amBUSForm 8.3 - The Allergy Therapeutics Plc
6th Apr 20232:01 pmRNS£40.75 million Facility with Equity Financing
6th Apr 20232:01 pmRNSStatement Regarding Possible Mandatory Cash Offer
6th Apr 20232:00 pmRNSTrading and Business Update
29th Mar 20237:00 amRNSPublication of Interim Results Delayed
27th Mar 20237:00 amRNSPatients dosed in VLP Peanut PROTECT trial
8th Mar 20235:28 pmRNSBlock Listing Interim Review
3rd Mar 20237:00 amRNSPDMR Dealing
7th Feb 20236:29 pmRNSResult of AGM
20th Jan 20237:00 amRNSHalf-Year Trading Update 2023
13th Jan 20235:27 pmRNSNOTICE OF 2022 ANNUAL GENERAL MEETING
3rd Jan 20237:30 amRNSSuspension - Allergy Therapeutics plc
29th Dec 202211:05 amRNSSecond Price Monitoring Extn
29th Dec 202211:00 amRNSPrice Monitoring Extension
29th Dec 20229:05 amRNSSecond Price Monitoring Extn
29th Dec 20229:00 amRNSPrice Monitoring Extension
29th Dec 20227:00 amRNSAnnual Report and Accounts Delayed
28th Dec 20227:00 amRNSDirector Resignation
8th Dec 20227:00 amRNSKey updates on Grass MATA MPL and VLP Peanut
6th Dec 20227:00 amRNSAppointment of Non-Executive Directors
21st Nov 20227:00 amRNSAppointment of Interim CFO
28th Oct 20227:00 amRNSAllergy to resume UK manufacturing production
19th Oct 20223:39 pmRNSHolding(s) in Company
17th Oct 20221:27 pmRNSAllergy Therapeutics – Result of GM
4th Oct 20227:00 amRNSUK manufacturing update
29th Sep 202212:00 pmRNSAllergy Therapeutics at Investor Meet Company
29th Sep 20227:00 amRNSSubscription and Debt Financing
29th Sep 20227:00 amRNSUnaudited Preliminary Results 2022
5th Sep 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference
2nd Sep 20224:50 pmRNSTotal Voting Rights
2nd Aug 202212:58 pmRNSBlock Listing Interim Review
15th Jul 20227:00 amRNSTrading Update and Notice of Results
1st Jul 20227:00 amRNSAllergy Therapeutics at EAACI Congress 2022
26th May 20227:00 amRNSNick Wykeman to step down as CFO
23rd May 20227:00 amRNSAllergy Therapeutics at H.C. Wainwright Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.